GUH-10582-44588
4 vaccinations
3 coded responses
55 check-ins
3 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 019 / MA
- Registered
- 2020-12-31
- Relationship
- Self
- Race
- N/A
- Ethnicity
- Hispanic or Latino
Registered dependents
N3D-97798-47605
Child or adolescent in my care · Male · 2022-12-19
FTC-19171-89703
Child or adolescent in my care · Male · 2023-03-22
Timeline
-
2020-12-31
Registered in v-safe
-
2020-12-31
Dose 1 — Moderna
- 2020-12-31
- 2021-01-01
- 2021-01-02
- 2021-01-03
- 2021-01-04
- 2021-01-05
- 2021-01-06
- 2021-01-07
- 2021-01-14
- 2021-01-21
-
2021-01-28
Dose 2 — Moderna
- 2021-01-28
-
2021-01-29
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-01-31
- 2021-02-01
- 2021-02-02
- 2021-02-03
- 2021-02-06
- 2021-02-11
- 2021-02-18
- 2021-02-25
- 2021-03-04
- 2021-03-11
-
2021-04-29
Survey response — 3 months, dose 2MedDRA: Headache — Feeling: FairFree text: HeadacheMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-07-29
- 2022-01-28
-
2022-02-18
Dose 3 — Moderna
- 2022-02-18
- 2022-02-19
- 2022-02-20
- 2022-02-21
- 2022-02-22
- 2022-02-23
- 2022-02-24
- 2022-02-25
- 2022-03-04
- 2022-03-11
- 2022-03-18
- 2022-03-25
- 2022-04-01
-
2022-05-20
Survey response — 3 months, dose 3MedDRA: Chest pain, Cough, Fatigue, Headache, Oropharyngeal pain, Pyrexia, Respiratory tract congestion, Rhinorrhoea — Feeling: Fair · Be unable to work or attend school, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Cough, sore throat, congested, runny nose, fever, headache, chest pain, fatigueMedDRA releases: 2024-11 · check-in free text available
-
2022-05-20
Report sent to call center — 3 months, dose 3Be unable to work or attend school · Get care from a doctor or other healthcare professionalTelehealth, virtual health, or email health consultation · 1 call case(s)
-
2022-05-23
Call successfulNot applicable - Accidental Reporting
- 2022-08-19
-
2022-12-08
Dose 4 — Pfizer-BioNTech
- 2022-12-08
- 2022-12-09
- 2022-12-10
- 2022-12-11
- 2022-12-12
- 2022-12-13
- 2022-12-14
- 2022-12-15
- 2022-12-22
-
2022-12-29
Survey response — day 21, dose 4MedDRA: Cough, Headache, Rhinorrhoea — Feeling: FairFree text: Headache, cough, runny noseMedDRA releases: 2024-11 · check-in free text available
- 2023-01-05
- 2023-01-12
- 2023-01-19
- 2023-03-09
- 2023-06-08
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-31 | Moderna | |
| 2 | 2021-01-28 | Moderna | |
| 3 | 2022-02-18 | Moderna | No |
| 4 | 2022-12-08 | Pfizer-BioNTech | No |
Call center
1 call center case
1 successful
Free text
Release 8 — 3 months, dose 2
Symptoms: Headache
Release 11 — 3 months, dose 3
Symptoms: Cough, sore throat, congested, runny nose, fever, headache, chest pain, fatigue
Release 12 — day 21, dose 4
Symptoms: Headache, cough, runny nose
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Chest pain | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Headache | ✓ | ✓ | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release